Cutanea Life Sciences, Inc. (CLS), a U.S. prescription product development company, unveiled its new digital presence, www.cutanea.com, to the dermatology community in conjunction with the 2016 American Academy of Dermatology Annual meeting in Washington, DC.
The company is developing several product candidates in different stages of development that cover an array of skin conditions, including acne, rosacea, psoriasis and warts caused by human papillomavirus (HPV).
“Our goal is to address the unmet and underserved needs of patients and health care professionals in the dermatology market,” said Robert J. Bitterman, Sr., president and chief executive officer of CLS. “Undesired skin conditions can impact a person’s health, appearance and self-esteem. Medications which are safe, effective, convenient and affordable are needed to better manage and control various disorders so patients will not be troubled by the psychological burdens of these conditions.”
